<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="deo270021" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">DEN Open</journal-id><journal-id journal-id-type="iso-abbrev">DEN Open</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2692-4609</journal-id><journal-id journal-id-type="publisher-id">DEO2</journal-id><journal-title-group><journal-title>DEN Open</journal-title></journal-title-group><issn pub-type="epub">2692-4609</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39372285</article-id><article-id pub-id-type="pmc">PMC11452608</article-id>
<article-id pub-id-type="doi">10.1002/deo2.70021</article-id><article-id pub-id-type="publisher-id">DEO270021</article-id><article-categories><subj-group subj-group-type="overline"><subject>Review</subject></subj-group><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Long&#x02010;term efficacy (at and beyond 1 year) of gastric peroral endoscopic myotomy for refractory gastroparesis: A systematic review and meta&#x02010;analysis</article-title><alt-title alt-title-type="left-running-head">MANDARINO <sc>et al</sc>.</alt-title></title-group><contrib-group><contrib id="deo270021-cr-0001" contrib-type="author" corresp="yes"><name><surname>Mandarino</surname><given-names>Francesco Vito</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9931-7221</contrib-id><xref rid="deo270021-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>mandarino.francesco@hsr.it</email></address></contrib><contrib id="deo270021-cr-0002" contrib-type="author"><name><surname>Barchi</surname><given-names>Alberto</given-names></name><xref rid="deo270021-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270021-cr-0003" contrib-type="author"><name><surname>Salmeri</surname><given-names>Noemi</given-names></name><xref rid="deo270021-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="deo270021-cr-0004" contrib-type="author"><name><surname>Azzolini</surname><given-names>Francesco</given-names></name><xref rid="deo270021-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270021-cr-0005" contrib-type="author"><name><surname>Fasulo</surname><given-names>Ernesto</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0009-3967-2684</contrib-id><xref rid="deo270021-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270021-cr-0006" contrib-type="author"><name><surname>Dell'Anna</surname><given-names>Giuseppe</given-names></name><xref rid="deo270021-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270021-cr-0007" contrib-type="author"><name><surname>Vespa</surname><given-names>Edoardo</given-names></name><xref rid="deo270021-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270021-cr-0008" contrib-type="author"><name><surname>Sinagra</surname><given-names>Emanuele</given-names></name><xref rid="deo270021-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="deo270021-cr-0009" contrib-type="author"><name><surname>Jacques</surname><given-names>Jeremie</given-names></name><xref rid="deo270021-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="deo270021-cr-0010" contrib-type="author"><name><surname>Danese</surname><given-names>Silvio</given-names></name><xref rid="deo270021-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="deo270021-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Division of Gastroenterology and Gastrointestinal Endoscopy</named-content>
<institution>IRCCS San Raffaele Scientific Institute, Vita&#x02010;Salute San Raffaele University</institution>
<city>Milan</city>
<country country="IT">Italy</country>
</aff><aff id="deo270021-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>Gynecology/Obstetrics Unit, IRCCS San Raffaele Hospital</institution>
<institution>Vita&#x02010;Salute San Raffaele University</institution>
<city>Milan</city>
<country country="IT">Italy</country>
</aff><aff id="deo270021-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>Gastroenterology and Endoscopy Unit, Fondazione Istituto G. Giglio, Contrada Pietra Pollastra Pisciotto</institution>
<city>Cefalu</city>
<country country="IT">Italy</country>
</aff><aff id="deo270021-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Gastroenterology and Endoscopy</named-content>
<institution>Dupuytren University Hospital</institution>
<city>Limoges</city>
<country country="FR">France</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>Francesco Vito Mandarino, Department of Gastroenterology and gastrointestinal endoscopy, IRCCS San Raffaele Hospital, Via Olgettina 60, Milan, Italy.<break/> Email: <email>mandarino.francesco@hsr.it</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>04</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2025</year></pub-date><volume>5</volume><issue seq="73">1</issue><issue-id pub-id-type="doi">10.1002/deo2.v5.1</issue-id><elocation-id>e70021</elocation-id><history>
<date date-type="rev-recd"><day>01</day><month>9</month><year>2024</year></date>
<date date-type="received"><day>08</day><month>7</month><year>2024</year></date>
<date date-type="accepted"><day>18</day><month>9</month><year>2024</year></date>
</history><permissions><!--&#x000a9; 2025 John Wiley & Sons Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2024 The Author(s). <italic toggle="yes">DEN Open</italic> published by John Wiley &#x00026; Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:DEO2-5-e70021.pdf"/><abstract><title>Abstract</title><sec id="deo270021-sec-0010"><title>Introduction</title><p>Although gastric peroral endoscopic myotomy (G&#x02010;POEM) has shown substantial efficacy in patients with medically refractory gastroparesis (GP), comprehensive long&#x02010;term data on its effectiveness are lacking.</p></sec><sec id="deo270021-sec-0020"><title>Methods</title><p>We conducted a systematic review and meta&#x02010;analysis including observational studies assessing long&#x02010;term efficacy after G&#x02010;POEM in patients with refractory GP. Our primary outcome was the pooled rate of clinical success 1&#x02010;year after G&#x02010;POEM. Secondary outcomes included clinical success at 2 and 3 years and the rate of adverse events according to the American Society for Gastrointestinal Endoscopy classification.</p></sec><sec id="deo270021-sec-0030"><title>Results</title><p>Thirteen studies, involving 952 patients with refractory GP undergoing G&#x02010;POEM, were eligible. The pooled 1 year&#x02010;clinical success was 0.72 (95% confidence interval [CI]: 0.56, 0.85, I<sup>2</sup> = 94.9%). The clinical success was 0.67 (95% CI: 0.47, 0.97, I<sup>2</sup> = 95.8%) when considering only studies defining success as 1 point decrease in Gastroparesis Cardinal Symptoms Index score and at least 25% decrease in two subscales. For patients who had 1&#x02010;year success, the pooled clinical success at 2 and 3 years were 0.71 (95% CI: 0.45, 0.92, I<sup>2</sup> = 94.9%) and 0.58 (95% CI: 0.19, 0.92, I<sup>2</sup> = 97.1%), respectively. The pooled rate of adverse events was 0.08 (95% CI: 0.06, 0.10, I<sup>2</sup> = 0%).</p></sec><sec id="deo270021-sec-0040"><title>Conclusion</title><p>G&#x02010;POEM is associated with successful outcomes in about 70% of treated cases after 1 year, with durable long&#x02010;term effects lasting up to 3 years. In the future, new uniform outcome definitions and strict patient selection criteria are warranted to delineate G&#x02010;POEM outcomes more accurately.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="deo270021-kwd-0001">gastric peroral endoscopic myotomy</kwd><kwd id="deo270021-kwd-0002">gastroparesis</kwd><kwd id="deo270021-kwd-0003">G&#x02010;POEM</kwd><kwd id="deo270021-kwd-0004">myotomy</kwd><kwd id="deo270021-kwd-0005">refractory</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>This study was supported by San Raffaele Hospital.</funding-source></award-group></funding-group><counts><fig-count count="4"/><table-count count="5"/><page-count count="12"/><word-count count="6817"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:27.02.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group><fn fn-type="equal" id="deo270021-note-0001"><p>Francesco Vito Mandarino and Alberto Barchi contributed equally to the work</p></fn></fn-group></notes></front><body><sec id="deo270021-sec-0050"><title>INTRODUCTION</title><p>Gastroparesis (GP) is a chronic condition characterized by delayed gastric emptying (GE) of foods in the absence of mechanical obstruction of the stomach.<xref rid="deo270021-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>
</p><p>Individuals with GP experience debilitating symptoms, such as vomiting, nausea, early satiety, and postprandial fullness, which can significantly decrease their quality of life. The healthcare costs associated with GP, including emergency room visits, inpatient admissions, and clinical consults, have dramatically increased in the last 20 years. In 2017, the estimated annual healthcare cost for GP in the United States was more than $500 million, and it is presumed to be on the rise.<xref rid="deo270021-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>
</p><p>The etiology of GP is diverse and is associated with conditions like diabetes, post&#x02010;surgical states, autoimmune diseases, and neurological disorders. It is believed that viral infections are implicated in up to 20% of GP cases. However, in over 50% of cases, a single cause is not identified, leading to the classification of idiopathic GP.<xref rid="deo270021-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>
</p><p>The growing interest in pyloric sphincter dysfunction as a mechanism of delayed GE in GP has prompted the development of pylorus&#x02010;targeted therapies for patients affected by disease refractory to pharmacological treatment. Over time, various endoscopic techniques have been developed. Although initially promising, botulinum toxin injection has not shown significant benefit compared to placebo,<xref rid="deo270021-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> while pyloric dilation has resulted in symptom improvement in fewer than 50% of cases.<xref rid="deo270021-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>
</p><p>Gastric peroral endoscopic myotomy (G&#x02010;POEM), introduced in 2013 by Khashab's group, has emerged as an effective treatment for refractory GP. G&#x02010;POEM potentially offers greater clinical success than surgical pyloromyotomy, with lower costs and shorter hospital stays.<xref rid="deo270021-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>
</p><p>However, although the first randomized controlled trial on G&#x02010;POEM demonstrated the superiority over the sham procedure,<xref rid="deo270021-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> there are still questions regarding the less&#x02010;than&#x02010;optimal success rate of the procedure. Additionally, evidence on long&#x02010;term outcomes and comprehensive data assessing the duration of G&#x02010;POEM's efficacy over time is lacking. This systematic review and meta&#x02010;analysis aims to evaluate the clinical efficacy of G&#x02010;POEM at 1 year, with a secondary focus on outcomes beyond 12 months.</p></sec><sec id="deo270021-sec-0060"><title>MATERIAL AND METHODS</title><sec id="deo270021-sec-0070"><title>Protocol</title><p>We adhered to the Preferred Reporting Items for Systematic Reviews and Meta&#x02010;analysis (PRISMA) guidelines (Table <xref rid="deo270021-supinfo-0001" ref-type="">S1</xref>) for this systematic review.<xref rid="deo270021-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> The study protocol was prospectively registered at the International Prospective Register of Systematic Reviews (PROSPERO), accessible at <ext-link xlink:href="https://www.crd.york.ac.uk/prospero" ext-link-type="uri">https://www.crd.york.ac.uk/prospero</ext-link> (ID: CRD42022369842).</p></sec><sec id="deo270021-sec-0080"><title>Search strategy</title><p>We performed a systematic literature search from inception to May 2023 using PubMed, Medline, Embase, Web of Science, and Cochrane databases. The literature search was based on a combination of the following search terms: &#x0201c;<italic toggle="yes">gastroparesis</italic>&#x0201d;, &#x0201c;<italic toggle="yes">myotomy</italic>&#x0201d;, &#x0201c;<italic toggle="yes">endoscopic treatment</italic>&#x0201d;, and &#x0201c;<italic toggle="yes">long&#x02010;term</italic>&#x0201d;. The complete search strategy is detailed in Table <xref rid="deo270021-supinfo-0001" ref-type="">S2</xref>.</p><p>We screened only English&#x02010;language and peer&#x02010;reviewed articles, removing duplicates using Rayyan (Clarivate), a bibliographic database manager. Article eligibility was initially assessed by titles and abstracts, followed by thorough full&#x02010;text reviews. The screening was conducted by Alberto Barchi and Emanuele Sinagra, and full&#x02010;text evaluations were by Francesco Vito Mandarino and Alberto Barchi Disagreements were reconciled by consulting a third investigator (Francesco Azzolini).</p></sec><sec id="deo270021-sec-0090"><title>Eligibility criteria</title><p>We included observational studies addressing outcomes of at least 1&#x02010;year post&#x02010;G&#x02010;POEM in patients with refractory GP. Exclusion criteria were pediatric cohorts, short&#x02010;term studies, non&#x02010;human studies, case reports, letters, narrative and systematic reviews, and studies lacking full text. Studies assessing efficacy beyond 1 year without data on 1&#x02010;year success were excluded.</p></sec><sec id="deo270021-sec-0100"><title>Data extraction</title><p>Data from original studies were extracted by two independent reviewers (Alberto Barchi and Ernesto Fasulo). Any discrepancies in data extraction were resolved under the supervision of Francesco Vito Mandarino.</p><p>The extracted data included: author; publication year; country; study design; patients&#x02019; number; demographic details (age, sex, and body mass index [BMI]); GP etiology; indication criteria for G&#x02010;POEM; prior endoscopic treatments; myotomy details; procedural time; technical success; clinical success definition; pre&#x02010; and post&#x02010;operative Gastric Emptying Study (GES) and Gastroparesis Cardinal Symptom Index (GCSI) scores<xref rid="deo270021-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>; clinical success; adverse events (AEs); follow&#x02010;up duration. When available, pre&#x02010; and post&#x02010;operative endoscopic functional luminal imaging probe (EndoFLIP) parameters and predictors of G&#x02010;POEM success or failure were also recorded.</p></sec><sec id="deo270021-sec-0110"><title>Quality assessment</title><p>The risk of bias in the studies was assessed using the Newcastle&#x02010;Ottawa Scale (NOS), a tool designed for assessing the quality of non&#x02010;randomized studies in meta&#x02010;analysis.<xref rid="deo270021-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> The NOS score focuses on three key aspects, specifically the selection of study groups, the comparability of groups, and the ascertainment of the outcome. The risk of bias was evaluated by two independent reviewers (Francesco Vito Mandarino and Alberto Barchi), and a third reviewer (Emanuele Sinagra) in case of disagreement.</p></sec><sec id="deo270021-sec-0120"><title>Assessment of publication bias</title><p>Funnel plots inspection for asymmetry together with rank correlation tests (Begg's test) was used to assess publication bias in the analyses of 1&#x02010;year, and overall AEs. We decided to use the Begg test (or Rank Correlation Test) for several considerations: a) the limited number of studies included in this meta&#x02010;analysis and their observational design, which are known factors that can influence the results of the Egger test and increase the likelihood of false positives; and b) the Begg test is more suitable for small sample sizes, as it does not assume a normal distribution of standard errors.</p><p>Funnel plots and rank correlation tests were conducted using Jamovi (<italic toggle="yes">Jamovi project</italic>, version 2.3).</p></sec><sec id="deo270021-sec-0130"><title>Outcomes</title><p>Our primary outcome was the pooled rate of clinical success 1&#x02010;year after G&#x02010;POEM. Secondary outcomes included pooled rates of success at 2 and 3 years for patients who had clinical success at 1 year, the pooled mean GCSI score pre&#x02010;procedure, differences in GCSI score from baseline to post&#x02010;G&#x02010;POEM, pooled mean pre&#x02010; and post&#x02010;procedural GES scores, differences in pre&#x02010; and post&#x02010;procedural GES parameters, and the AEs rate.</p><p>The definition of clinical success varied slightly across studies. The most recent definition was a decrease of 1 point in the total GCSI score plus at least a &#x0003e;25% decrease in two subscales.<xref rid="deo270021-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> However, due to the lack of a consensus, other definitions were also accepted and considered in subgroup analysis.</p><p>AEs were categorized following the American Society for Gastrointestinal Endoscopy (ASGE) lexicon classification.<xref rid="deo270021-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>
</p><p>For studies on the same prospective cohort, pooled analysis of the secondary outcomes was obtained retaining only the larger cohort.</p></sec><sec id="deo270021-sec-0140"><title>Data synthesis and statistical analysis</title><p>For continuous outcomes, specifically GCSI scores pre&#x02010;, at 1&#x02010; and 2&#x02010;years post&#x02010;procedure, and GES parameters pre&#x02010; and post&#x02010;procedural, we calculated pooled mean difference (MD) with 95% CI.</p><p>Variables expressed as median and range or median and interquartile range (IQR) were converted into mean and standard deviation (SD) for pooling, using appropriate methods.<xref rid="deo270021-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> After assessing skewness using the method by Shi et&#x000a0;al.,<xref rid="deo270021-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> if the data did not show significant skewness from normality, we extrapolated the mean from median values using the method by Luo et&#x000a0;al.<xref rid="deo270021-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> and calculated the SD from the IQR or range using the equation by Wan et&#x000a0;al., when either of these measures was available.<xref rid="deo270021-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> The equation by Shi et&#x000a0;al. was applied if both the range and IQR were available.<xref rid="deo270021-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> If the standard error of the mean (SEM) was available, SD was calculated using the Cochrane&#x02010;approved method: SD = SEM &#x000d7; &#x0221a;N.<xref rid="deo270021-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>
</p><p>For binary outcomes, specifically clinical success at 1 year, 2 years, and 3 years, and AEs, we calculated pooled proportions with 95% confidence intervals (CIs). For 1&#x02010;year clinical success, the total number of patients with follow&#x02010;up was used as the denominator. For the analysis of post&#x02010;G&#x02010;POEM efficacy at 2 and 3 years, we used as denominator only the number of patients with clinical success at 1 year. When more than one study was conducted on the same clinical cohort, we included only the study with the largest available cohort.</p><p>Subgroup analyses for the primary outcome (clinical success at 1 year) were performed for studies enrolling patients with GP and Percent Gastric Retention (PGR) &#x0003e; 10% and for studies using the most recent definition of clinical success, as beforementioned.<xref rid="deo270021-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> Leave&#x02010;One&#x02010;Out (LOO) sensitivity analyses were performed to evaluate the robustness of the overall effect measure.</p><p>The homogeneity of effect sizes among pooled studies was assessed using Cochran's Q test, with the corresponding p&#x02010;value reported alongside the I<sup>2</sup> statistic. I<sup>2</sup> values were interpreted according to Higgins et&#x000a0;al. definition.<xref rid="deo270021-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>
</p><p>The random effects model was applied in both the primary analyses and the subgroup analyses. This approach is indeed suitable for considering inter&#x02010;study variability in pooled estimates and is usually preferred in meta&#x02010;analysis of clinical studies where substantial heterogeneity is usually present.</p><p>Analyses were performed using the software Open Meta&#x02010;analyst (CEBM; Brown University).</p><p>Predictive factors of success and EndoFLIP parameters were also examined. Formal analyses of these data could not be performed as they were not consistently reported and were presented descriptively among the results.</p></sec></sec><sec id="deo270021-sec-0150"><title>RESULTS</title><p>The literature search identified 1713 articles, from which 11 were removed as duplicates and 1618 were excluded after reviewing the title and abstract. Eighty&#x02010;four articles were then screened for inclusion criteria. Of these, 69 were excluded for various reasons: not being full articles (31 studies), having a follow&#x02010;up period shorter than 12 months post&#x02010;G&#x02010;POEM (20 studies), not reporting data on the primary outcome (15 studies), being non&#x02010;English (two studies), reporting data of 1&#x02010;year efficacy from the same cohort of patients (two studies), or reporting outcomes beyond 12 months without 1&#x02010;year efficacy data (one study). Ultimately, 13 studies comprising 952 patients with refractory GP undergoing G&#x02010;POEM were eligible for the systematic review and meta&#x02010;analysis<xref rid="deo270021-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="deo270021-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="deo270021-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="deo270021-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="deo270021-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="deo270021-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="deo270021-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="deo270021-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="deo270021-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="deo270021-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="deo270021-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="deo270021-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>, <xref rid="deo270021-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> (Figure <xref rid="deo270021-supinfo-0001" ref-type="">S1</xref>). Tables&#x000a0;<xref rid="deo270021-tbl-0001" ref-type="table">1</xref>, <xref rid="deo270021-tbl-0002" ref-type="table">2</xref>, <xref rid="deo270021-tbl-0003" ref-type="table">3</xref>, <xref rid="deo270021-tbl-0004" ref-type="table">4</xref>, <xref rid="deo270021-tbl-0005" ref-type="table">5</xref> detail the baseline characteristics, endoscopic details, outcomes, and adverse events of the studies.</p><table-wrap position="float" id="deo270021-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Baseline characteristics.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" colspan="3" style="border-bottom:solid 1px #000000" rowspan="1">GP etiology, <italic toggle="yes">n</italic> (%)</th><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" colspan="3" style="border-bottom:solid 1px #000000" rowspan="1">Pre&#x02010;operative GES, mean (SD)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Author</th><th align="left" rowspan="1" colspan="1">Year</th><th align="left" rowspan="1" colspan="1">Country</th><th align="left" rowspan="1" colspan="1">Study design</th><th align="left" rowspan="1" colspan="1">Multiple or single&#x02010;center</th><th align="left" rowspan="1" colspan="1">Patients (<italic toggle="yes">n</italic>)</th><th align="left" rowspan="1" colspan="1">Male, <italic toggle="yes">n</italic> (%)</th><th align="left" rowspan="1" colspan="1">Age, mean (SD)</th><th align="left" rowspan="1" colspan="1">BMI, mean (SD)</th><th align="left" rowspan="1" colspan="1">Diabetes</th><th align="left" rowspan="1" colspan="1">Idiopathic</th><th align="left" rowspan="1" colspan="1">Post&#x02010;surgery</th><th align="left" rowspan="1" colspan="1">Indication for G&#x02010;POEM</th><th align="left" rowspan="1" colspan="1">Previous endoscopic treatment, <italic toggle="yes">n</italic> (%)</th><th align="left" rowspan="1" colspan="1">Pre&#x02010;operative GCSI, mean (SD)</th><th align="left" rowspan="1" colspan="1">2 h PGR (%)</th><th align="left" rowspan="1" colspan="1">4 h PGR (%)</th><th align="left" rowspan="1" colspan="1">T &#x000bd; (min)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Abdelfatah et al</td><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">USA</td><td align="left" rowspan="1" colspan="1">Retrospective</td><td align="left" rowspan="1" colspan="1">Single&#x02010;center</td><td align="left" rowspan="1" colspan="1">90</td><td align="left" rowspan="1" colspan="1">17 (19)</td><td align="left" rowspan="1" colspan="1">42.4 (12.6)</td><td align="left" rowspan="1" colspan="1">27.7 (7.4)</td><td align="left" rowspan="1" colspan="1">38 (42)</td><td align="left" rowspan="1" colspan="1">42 (47)</td><td align="left" rowspan="1" colspan="1">10 (11)</td><td align="left" rowspan="1" colspan="1">Refractory GP with 4 h PGR &#x02265; 10%</td><td align="left" rowspan="1" colspan="1">6 (6.7%)</td><td align="left" rowspan="1" colspan="1">3.8 (0.6)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">50.6 (27.3)</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Gregor et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">USA</td><td align="left" rowspan="1" colspan="1">Prospective</td><td align="left" rowspan="1" colspan="1">Single&#x02010;center</td><td align="left" rowspan="1" colspan="1">52</td><td align="left" rowspan="1" colspan="1">6 (11.5)</td><td align="left" rowspan="1" colspan="1">49.8 (15.9)</td><td align="left" rowspan="1" colspan="1">28.7 (7.2)</td><td align="left" rowspan="1" colspan="1">21 (40.4)</td><td align="left" rowspan="1" colspan="1">21 (40.4)</td><td align="left" rowspan="1" colspan="1">10 (19.2)</td><td align="left" rowspan="1" colspan="1">Refractory GP with 4 h PGR &#x02265; 10%</td><td align="left" rowspan="1" colspan="1">16 (43.2)</td><td align="left" rowspan="1" colspan="1">3.4 (1.0)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">36.5 (22.6)</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Hernandez Mondragon et al</td><td align="left" rowspan="1" colspan="1">2022</td><td align="left" rowspan="1" colspan="1">Mexico</td><td align="left" rowspan="1" colspan="1">Retrospective</td><td align="left" rowspan="1" colspan="1">Single&#x02010;center</td><td align="left" rowspan="1" colspan="1">374</td><td align="left" rowspan="1" colspan="1">141 (24.5)</td><td align="left" rowspan="1" colspan="1">48.4 (15.7)</td><td align="left" rowspan="1" colspan="1">26.4 (4.7)</td><td align="left" rowspan="1" colspan="1">141 (37.7)</td><td align="left" rowspan="1" colspan="1">115 (30.7)</td><td align="left" rowspan="1" colspan="1">102 (27.3)</td><td align="left" rowspan="1" colspan="1">Refractory GP with 4 h PGR &#x0003e; 10% and t &#x000bd; &#x0003e; 150 min</td><td align="left" rowspan="1" colspan="1">61 (10.6)</td><td align="left" rowspan="1" colspan="1">3.8 (0.5)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">40.8 (42.4)</td><td align="left" rowspan="1" colspan="1">246 med (150&#x02013;368)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hustak et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">2020</td><td align="left" rowspan="1" colspan="1">Czech Republic</td><td align="left" rowspan="1" colspan="1">Retrospective</td><td align="left" rowspan="1" colspan="1">Single&#x02010;center</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">4 (44.4)</td><td align="left" rowspan="1" colspan="1">53.4 (37.6)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">3 (33.3)</td><td align="left" rowspan="1" colspan="1">1 (11.1)</td><td align="left" rowspan="1" colspan="1">5 (55.5)</td><td align="left" rowspan="1" colspan="1">Refractory GP with 2 h PGR &#x02265; 60%</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">3.2 (0.8)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Labonde et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">2022</td><td align="left" rowspan="1" colspan="1">France</td><td align="left" rowspan="1" colspan="1">Retrospective</td><td align="left" rowspan="1" colspan="1">Multicenter</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">15 (32.6)</td><td align="left" rowspan="1" colspan="1">54 (15.9)</td><td align="left" rowspan="1" colspan="1">22.9 (5.4)</td><td align="left" rowspan="1" colspan="1">15 (32.6)</td><td align="left" rowspan="1" colspan="1">16 (34.8)</td><td align="left" rowspan="1" colspan="1">9 (19.6)</td><td align="left" rowspan="1" colspan="1">Refractory GP with 4 h PGR &#x02265; 10%</td><td align="left" rowspan="1" colspan="1">5 (10.9)</td><td align="left" rowspan="1" colspan="1">4.3 med (2.8&#x02013;3.5)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">50.2 (27.6)</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Tan et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">Retrospective</td><td align="left" rowspan="1" colspan="1">Single&#x02010;center</td><td align="left" rowspan="1" colspan="1">79</td><td align="left" rowspan="1" colspan="1">57 (72.1)</td><td align="left" rowspan="1" colspan="1">65.7 (11.1)</td><td align="left" rowspan="1" colspan="1">19.7 (3.5)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">79 (100)</td><td align="left" rowspan="1" colspan="1">Refractory GP with GCSI &#x02265; 2.3</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">3.0 (0.6)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Vosoughi et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">2020</td><td align="left" rowspan="1" colspan="1">USA</td><td align="left" rowspan="1" colspan="1">Retrospective</td><td align="left" rowspan="1" colspan="1">Multicenter</td><td align="left" rowspan="1" colspan="1">37</td><td align="left" rowspan="1" colspan="1">13 (35.1)</td><td align="left" rowspan="1" colspan="1">56.2 (12.7)</td><td align="left" rowspan="1" colspan="1">25.9 (5.1)</td><td align="left" rowspan="1" colspan="1">12 (32.4)</td><td align="left" rowspan="1" colspan="1">10 (27)</td><td align="left" rowspan="1" colspan="1">10 (27)</td><td align="left" rowspan="1" colspan="1">Refractory GP</td><td align="left" rowspan="1" colspan="1">16 (43.2)</td><td align="left" rowspan="1" colspan="1">3.3 (1.1)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Ragi et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">France</td><td align="left" rowspan="1" colspan="1">Retrospective</td><td align="left" rowspan="1" colspan="1">Multicenter</td><td align="left" rowspan="1" colspan="1">76</td><td align="left" rowspan="1" colspan="1">30 (39.5)</td><td align="left" rowspan="1" colspan="1">51.2 (37.7)</td><td align="left" rowspan="1" colspan="1">23.7 (6.0)</td><td align="left" rowspan="1" colspan="1">26 (34.2)</td><td align="left" rowspan="1" colspan="1">27 (35.5)</td><td align="left" rowspan="1" colspan="1">15 (19.7)</td><td align="left" rowspan="1" colspan="1">Refractory GP with h PGR 30% or 4 h PGR &#x02265; 10%</td><td align="left" rowspan="1" colspan="1">13 (17.1)</td><td align="left" rowspan="1" colspan="1">3.6 med (2.8&#x02013;4.0)</td><td align="left" rowspan="1" colspan="1">79 (65&#x02013;90)</td><td align="left" rowspan="1" colspan="1">45 (29&#x02013;67)</td><td align="left" rowspan="1" colspan="1">180 med (140&#x02013;280)</td></tr><tr><td align="left" rowspan="1" colspan="1">Vosoughi et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">2022</td><td align="left" rowspan="1" colspan="1">USA</td><td align="left" rowspan="1" colspan="1">Retrospective</td><td align="left" rowspan="1" colspan="1">Multicenter</td><td align="left" rowspan="1" colspan="1">80</td><td align="left" rowspan="1" colspan="1">23 (28.7)</td><td align="left" rowspan="1" colspan="1">49.3 (14.9)</td><td align="left" rowspan="1" colspan="1">26.2 (6.0)</td><td align="left" rowspan="1" colspan="1">19 (23.8)</td><td align="left" rowspan="1" colspan="1">33 (41.3)</td><td align="left" rowspan="1" colspan="1">28 (35)</td><td align="left" rowspan="1" colspan="1">Refractory GP with impaired GE</td><td align="left" rowspan="1" colspan="1">56 (70)</td><td align="left" rowspan="1" colspan="1">2.8 (1.1)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">39 (22)</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Xu et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">2018</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">Prospective</td><td align="left" rowspan="1" colspan="1">Single&#x02010;center</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">11 (68.7)</td><td align="left" rowspan="1" colspan="1">58.5 (16.1)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">3 (18.8)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">13 (81.2)</td><td align="left" rowspan="1" colspan="1">Refractory GP with GCSI &#x02265; 20 and 2 h PGR &#x02265; 60%</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">69.3 (11.5)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">183.2 (77.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Kahaleh et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">2018</td><td align="left" rowspan="1" colspan="1">USA</td><td align="left" rowspan="1" colspan="1">Retrospective</td><td align="left" rowspan="1" colspan="1">Multicenter</td><td align="left" rowspan="1" colspan="1">33</td><td align="left" rowspan="1" colspan="1">11 (33.3)</td><td align="left" rowspan="1" colspan="1">52.5 (18.4)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">7 (21.2)</td><td align="left" rowspan="1" colspan="1">12 (36.4)</td><td align="left" rowspan="1" colspan="1">12 (36.4)</td><td align="left" rowspan="1" colspan="1">Refractory GP with abnormal GE</td><td align="left" rowspan="1" colspan="1">4 (12.1)</td><td align="left" rowspan="1" colspan="1">3.3</td><td align="left" rowspan="1" colspan="1">75.8</td><td align="left" rowspan="1" colspan="1">45</td><td align="left" rowspan="1" colspan="1">222.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Reja et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">2022</td><td align="left" rowspan="1" colspan="1">USA</td><td align="left" rowspan="1" colspan="1">Prospective</td><td align="left" rowspan="1" colspan="1">Single&#x02010;center</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">6 (16.7)</td><td align="left" rowspan="1" colspan="1">46.3 (1.75 SE)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">6 (16.7)</td><td align="left" rowspan="1" colspan="1">16 (44.4)</td><td align="left" rowspan="1" colspan="1">10 (27.8)</td><td align="left" rowspan="1" colspan="1">Refractory GP with delayed GE</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">4.0 (0.12 SE)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">275.1 (6.8 SE)</td></tr><tr><td align="left" rowspan="1" colspan="1">Conchillo et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">Netherlands</td><td align="left" rowspan="1" colspan="1">Prospective</td><td align="left" rowspan="1" colspan="1">Single&#x02010;center</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">3 (12.5)</td><td align="left" rowspan="1" colspan="1">55.3 (2.9)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">6 (25)</td><td align="left" rowspan="1" colspan="1">11 (45.8)</td><td align="left" rowspan="1" colspan="1">7 (29.2)</td><td align="left" rowspan="1" colspan="1">Refractory GP grade 3<xref rid="deo270021-tbl1-note-0002" ref-type="table-fn">
<sup>*</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">3.1 (0.1)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">240 (28)</td></tr></tbody></table><table-wrap-foot><fn id="deo270021-tbl1-note-0001"><p>Abbreviations: BMI, body mass index; GCSI, Gastric Cardinal Symptom Index; GE, gastric emptying; GES, gastric emptying study; GP, gastroparesis; med, median; NA, not available; PGR, percent gastric retention; SD, standard deviation; SE, standard error; t &#x000bd;, half gastric time.</p></fn><fn id="deo270021-tbl1-note-0002"><label>*</label><p>nutritional status unable to be maintained via oral intake, and frequent hospital admissions.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><table-wrap position="float" id="deo270021-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Endoscopic details and outcomes.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="center" colspan="3" style="border-bottom:solid 1px #000000" rowspan="1">Post&#x02010;operative GES, mean (SD)</th><th align="left" rowspan="1" colspan="1"/></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Author</th><th align="left" rowspan="1" colspan="1">MC location and myotomy type and</th><th align="left" rowspan="1" colspan="1">Procedural time, mean (SD) (min)</th><th align="left" rowspan="1" colspan="1">Technical success, <italic toggle="yes">n</italic> (%)</th><th align="left" rowspan="1" colspan="1">Definition of clinical success</th><th align="left" rowspan="1" colspan="1">1&#x02010;year clinical success, <italic toggle="yes">n</italic> (%)</th><th align="left" rowspan="1" colspan="1">2&#x02010;year clinical success, <italic toggle="yes">n</italic> (%)</th><th align="left" rowspan="1" colspan="1">3&#x02010;year clinical success, <italic toggle="yes">n</italic> (%)</th><th align="left" rowspan="1" colspan="1">GCSI at 12 months, mean (SD)</th><th align="left" rowspan="1" colspan="1">GCSI at 24 months, mean (SD)</th><th align="left" rowspan="1" colspan="1">GCSI at 36 months, mean (SD)</th><th align="left" rowspan="1" colspan="1">2 h PGR (%)</th><th align="left" rowspan="1" colspan="1">4 h PGR (%)</th><th align="left" rowspan="1" colspan="1">t &#x000bd; (min)</th><th align="left" rowspan="1" colspan="1">Follow&#x02010;up (months), mean (SD)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Abdelfatah et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">MC at the greater curve. Single (circular muscle) or double layer myotomy (preserving outer longitudinal fibers) myotomy</td><td align="left" rowspan="1" colspan="1">50 (13)</td><td align="left" rowspan="1" colspan="1">90/90 (100)</td><td align="left" rowspan="1" colspan="1">&#x02193; 1 point + 25% in 2 subscales in GCSI</td><td align="left" rowspan="1" colspan="1">44/83 (91.7)</td><td align="left" rowspan="1" colspan="1">20/21 (95.2)</td><td align="left" rowspan="1" colspan="1">6/7 (86)</td><td align="left" rowspan="1" colspan="1">2.3 (1.3)</td><td align="left" rowspan="1" colspan="1">1.6 (1.2)</td><td align="left" rowspan="1" colspan="1">1.1 (1.2)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">20.1 (23.5)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">36</td></tr><tr><td align="left" rowspan="1" colspan="1">Gregor et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">MC at the greater curvature. Full&#x02010;thickness pyloromyotomy</td><td align="left" rowspan="1" colspan="1">59 (17)</td><td align="left" rowspan="1" colspan="1">52/52 (100)</td><td align="left" rowspan="1" colspan="1">&#x02193; 1 point in GCSI</td><td align="left" rowspan="1" colspan="1">11/23 (48)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">2.4 (1.6)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">10.2 (11.7)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">24</td></tr><tr><td align="left" rowspan="1" colspan="1">Mondragon et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">MC at the greater or lesser curvature. Myotomy not detailed</td><td align="left" rowspan="1" colspan="1">55 (17.7)</td><td align="left" rowspan="1" colspan="1">374/374 (100)</td><td align="left" rowspan="1" colspan="1">&#x02193; 1 point + 25% in 2 subscales in GCSI</td><td align="left" rowspan="1" colspan="1">323/331 (97.6)</td><td align="left" rowspan="1" colspan="1">293/303 (96.7)</td><td align="left" rowspan="1" colspan="1">203/214 (94.8)</td><td align="left" rowspan="1" colspan="1">1.6 (0.5)</td><td align="left" rowspan="1" colspan="1">1.6 (0.4)</td><td align="left" rowspan="1" colspan="1">1.9 (0.6)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">9 (1&#x02010;35)</td><td align="left" rowspan="1" colspan="1">112 (67&#x02013;188)</td><td align="left" rowspan="1" colspan="1">48</td></tr><tr><td align="left" rowspan="1" colspan="1">Hustak et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">MC at the greater curvature. Full&#x02010;thickness pyloromyotomy</td><td align="left" rowspan="1" colspan="1">75 (23)</td><td align="left" rowspan="1" colspan="1">9/9 (100)</td><td align="left" rowspan="1" colspan="1">&#x02193; 40% in GCSI</td><td align="left" rowspan="1" colspan="1">8/9 (88.9)</td><td align="left" rowspan="1" colspan="1">3/4 (75)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">1.1 (0.6)</td><td align="left" rowspan="1" colspan="1">1.3 (0.8)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">24</td></tr><tr><td align="left" rowspan="1" colspan="1">Labonde et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">MC at the greater curvature. Full&#x02010;thickness pyloromyotomy</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">46/46 (100)</td><td align="left" rowspan="1" colspan="1">&#x02193; 1 point in GCSI</td><td align="left" rowspan="1" colspan="1">32/46 (69.5)</td><td align="left" rowspan="1" colspan="1">32/46 (69.5)</td><td align="left" rowspan="1" colspan="1">30/46 (65.2)</td><td align="left" rowspan="1" colspan="1">1.8</td><td align="left" rowspan="1" colspan="1">1.7</td><td align="left" rowspan="1" colspan="1">1.8</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">36</td></tr><tr><td align="left" rowspan="1" colspan="1">Tan et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">MC at the greater curvature. Full&#x02010;thickness pyloromyotomy</td><td align="left" rowspan="1" colspan="1">26.4 (4.2)</td><td align="left" rowspan="1" colspan="1">79/79 (100)</td><td align="left" rowspan="1" colspan="1">&#x02193; 25% in 2 subscales in GCSI</td><td align="left" rowspan="1" colspan="1">47/60 (78.3)</td><td align="left" rowspan="1" colspan="1">27/33 (81.8)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">1.0 (0.5)</td><td align="left" rowspan="1" colspan="1">0.9 (0.4)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">24</td></tr><tr><td align="left" rowspan="1" colspan="1">Vosoughi et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">MC at the greater curvature. Selective myotomy of the pyloric circular muscle</td><td align="left" rowspan="1" colspan="1">50 med (41&#x02013;65)</td><td align="left" rowspan="1" colspan="1">37/37 (100)</td><td align="left" rowspan="1" colspan="1">&#x02193; 1 point + 25% in 2 subscales in GCSI</td><td align="left" rowspan="1" colspan="1">26/37 (70.3)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">1.7 (1.2)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">12</td></tr><tr><td align="left" rowspan="1" colspan="1">Ragi et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">MC at the greater curvature. Myotomy not detailed</td><td align="left" rowspan="1" colspan="1">47 med (28&#x02013;78)</td><td align="left" rowspan="1" colspan="1">75/76 (98.6)</td><td align="left" rowspan="1" colspan="1">&#x02193; 1 point in GCSI</td><td align="left" rowspan="1" colspan="1">50/76 (65.8)</td><td align="left" rowspan="1" colspan="1">29/39 (74.4)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">1.9 med (1&#x02013;2.9)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">52 (27)</td><td align="left" rowspan="1" colspan="1">11.5 (27)</td><td align="left" rowspan="1" colspan="1">100.5 (196)</td><td align="left" rowspan="1" colspan="1">24</td></tr><tr><td align="left" rowspan="1" colspan="1">Vosoughi et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">MC at the greater curvature. Full&#x02010;thickness pyloromyotomy</td><td align="left" rowspan="1" colspan="1">43 med (34&#x02013;56.5)</td><td align="left" rowspan="1" colspan="1">80/80 (100)</td><td align="left" rowspan="1" colspan="1">&#x02193; 1 point + 25% in 2 subscales in GCSI</td><td align="left" rowspan="1" colspan="1">42/75 (56)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">1.5 (1.2)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">21 (27)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">12</td></tr><tr><td align="left" rowspan="1" colspan="1">Xu et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">MC at the greater curvature. Full&#x02010;thickness pyloromyotomy</td><td align="left" rowspan="1" colspan="1">45.3 (12.3)</td><td align="left" rowspan="1" colspan="1">16/16 (100)</td><td align="left" rowspan="1" colspan="1">&#x02193; 50% in GCSI</td><td align="left" rowspan="1" colspan="1">13/16 (81.3)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">33.4 (18.2)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">84.0 (34.7)</td><td align="left" rowspan="1" colspan="1">14 med (5&#x02013;19)</td></tr><tr><td align="left" rowspan="1" colspan="1">Kahaleh et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">MC at the greater curvature. Selective myotomy of the pyloric circular muscle</td><td align="left" rowspan="1" colspan="1">77.6 med (37&#x02010;255)</td><td align="left" rowspan="1" colspan="1">33/33 (100)</td><td align="left" rowspan="1" colspan="1">Improvement of GCSI</td><td align="left" rowspan="1" colspan="1">28/33 (85)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">0.8 (0.8)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">58.3</td><td align="left" rowspan="1" colspan="1">29.6</td><td align="left" rowspan="1" colspan="1">143.2</td><td align="left" rowspan="1" colspan="1">12</td></tr><tr><td align="left" rowspan="1" colspan="1">Reja et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">MC at the greater curvature. Full&#x02010;thickness pyloromyotomy</td><td align="left" rowspan="1" colspan="1">60.5 med (35&#x02010;136)</td><td align="left" rowspan="1" colspan="1">36/36 (100)</td><td align="left" rowspan="1" colspan="1">Improvement of GCSI</td><td align="left" rowspan="1" colspan="1">31/36 (86)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">1.94 (1.17 SE)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">192.7 (1 SE)</td><td align="left" rowspan="1" colspan="1">15 (1.05 SE)</td></tr><tr><td align="left" rowspan="1" colspan="1">Conchillo et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">54 (5)</td><td align="left" rowspan="1" colspan="1">24/24 (100)</td><td align="left" rowspan="1" colspan="1">&#x02193; 1 point in GCSI</td><td align="left" rowspan="1" colspan="1">8/24 (33.3)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">2.4 (0.2)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">228 (23)</td><td align="left" rowspan="1" colspan="1">12</td></tr></tbody></table><table-wrap-foot><fn id="deo270021-tbl2-note-0001"><p>&#x02193;decrease.</p></fn><fn id="deo270021-tbl2-note-0002"><p>Abbreviations: GCSI Gastric Cardinal Symptom Index; GES, Gastric Emptying Study; med, median; NA, not available; SE, standard error.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><table-wrap position="float" id="deo270021-tbl-0003" content-type="TABLE"><label>TABLE 3</label><caption><p>Adverse events according to the American Society for Gastrointestinal Endoscopy.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" colspan="3" style="border-bottom:solid 1px #000000" rowspan="1">Adverse events, <italic toggle="yes">n</italic> (%)</th><th align="left" rowspan="1" colspan="1"/></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Author</th><th align="left" rowspan="1" colspan="1">Mild<xref rid="deo270021-tbl3-note-0001" ref-type="table-fn">*</xref>
</th><th align="left" rowspan="1" colspan="1">Moderate<xref rid="deo270021-tbl3-note-0001" ref-type="table-fn">*</xref>, <italic toggle="yes">n</italic> (%)</th><th align="left" rowspan="1" colspan="1">Severe<xref rid="deo270021-tbl3-note-0001" ref-type="table-fn">*</xref>, <italic toggle="yes">n</italic> (%)</th><th align="left" rowspan="1" colspan="1">Description</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Abdelfatah et al</td><td align="left" rowspan="1" colspan="1">2 (2.2)</td><td align="left" rowspan="1" colspan="1">2 (2.2)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">Abdominal pain (one case), exacerbation of pre&#x02010;existing chronic respiratory disease (one case), capnoperitoneum (one case), and bleeding (one case)</td></tr><tr><td align="left" rowspan="1" colspan="1">Gregor et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">3 (5.8)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">Bleeding (one case) and leaks (two cases)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hernandez Mondragon et al</td><td align="left" rowspan="1" colspan="1">26 (6.9)</td><td align="left" rowspan="1" colspan="1">7 (1.8)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">Bleeding (17 cases), mucosal tear (eight cases), perforation (one case), clip dislodgment (two cases), and prepyloric ulcer (four cases)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hustak et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">2 (22.2)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">Bleeding (one case) and leak (one case)</td></tr><tr><td align="left" rowspan="1" colspan="1">Labonde et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Tan et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">7 (8.8)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">Abdominal pain (seven cases)</td></tr><tr><td align="left" rowspan="1" colspan="1">Vosoughi et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">5 (13.5)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">Mucosotomy (two cases) and perforation (three cases)</td></tr><tr><td align="left" rowspan="1" colspan="1">Ragi et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">7 (9.2)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">1 (1.3)</td><td align="left" rowspan="1" colspan="1">Abdominal pain and fever (one case), persistent abdominal pain (one case), functional occlusion (two cases), perforation (one case), bleeding (two cases), and abdominal abscess (one case)</td></tr><tr><td align="left" rowspan="1" colspan="1">Vosoughi et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">5 (6.2)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">Abdominal pain (three cases), mucosotomy (one case), and thermal mucosa injury (one case)</td></tr><tr><td align="left" rowspan="1" colspan="1">Xu et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">&#x02010;</td></tr><tr><td align="left" rowspan="1" colspan="1">Kahaleh et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">2 (6)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">Bleeding (one case) and ulcer (one case)</td></tr><tr><td align="left" rowspan="1" colspan="1">Reja et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">5 (13.8)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">Mucosotomy (five cases)</td></tr><tr><td align="left" rowspan="1" colspan="1">Conchillo et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">2 (8.3)</td><td align="left" rowspan="1" colspan="1">1 (4.2)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">Capnoperitoneum (two cases) and bleeding (one case)</td></tr></tbody></table><table-wrap-foot><fn id="deo270021-tbl3-note-0001"><label>*</label><p>Based on the American Society for Gastrointestinal Endoscopy.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><table-wrap position="float" id="deo270021-tbl-0004" content-type="TABLE"><label>TABLE 4</label><caption><p>Detailed adverse events.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" colspan="5" style="border-bottom:solid 1px #000000" rowspan="1">Adverse events, <italic toggle="yes">n</italic> (%)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Author</th><th align="left" rowspan="1" colspan="1">Abdominal pain</th><th align="left" rowspan="1" colspan="1">Capnoperitoneum</th><th align="left" rowspan="1" colspan="1">Bleeding/ulcer</th><th align="left" rowspan="1" colspan="1">Mucosotomy/leak</th><th align="left" rowspan="1" colspan="1">Perforation</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Abdelfatah et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">1 (1.1)</td><td align="left" rowspan="1" colspan="1">1 (1.1)</td><td align="left" rowspan="1" colspan="1">1 (1.1)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Gregor et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">1 (1.9)</td><td align="left" rowspan="1" colspan="1">2 (3.8)</td><td align="left" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Mondragon et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">21 (5.6)</td><td align="left" rowspan="1" colspan="1">8 (2.1)</td><td align="left" rowspan="1" colspan="1">1 (0.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hustak et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">1 (11.1)</td><td align="left" rowspan="1" colspan="1">1 (11.1)</td><td align="left" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Labonde et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Tan et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">7 (8.8)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Vosoughi et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">2 (5.4)</td><td align="left" rowspan="1" colspan="1">3 (8.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Ragi et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">7 (9.2)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">1 (1.3)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Vosoughi et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">3 (3.8)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">1 (1.3)</td><td align="left" rowspan="1" colspan="1">1 (1.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Xu et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Kahaleh et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">2 (6.0)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Reja et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">5 (13.9)</td><td align="left" rowspan="1" colspan="1">(0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Conchillo et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">2 (8.3)</td><td align="left" rowspan="1" colspan="1">1 (4.2)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">0 (0)</td></tr></tbody></table><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><table-wrap position="float" id="deo270021-tbl-0005" content-type="TABLE"><label>TABLE 5</label><caption><p>EndoFlip measures.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Author</th><th align="left" rowspan="1" colspan="1">Pre&#x02010;Endoflip DI 30 (mm<sup>2</sup>/mmHg), mean (SD)</th><th align="left" rowspan="1" colspan="1">Pre&#x02010;Endoflip DI 40 (mm<sup>2</sup>/mmHg), mean (SD)</th><th align="left" rowspan="1" colspan="1">Pre&#x02010;Endoflip DI 50 (mm<sup>2</sup>/mmHg), mean (SD)</th><th align="left" rowspan="1" colspan="1">Pre&#x02010;Endoflip CSA 30 (mm<sup>2</sup>), mean (SD)</th><th align="left" rowspan="1" colspan="1">Pre&#x02010;Endoflip CSA 40 (mm<sup>2</sup>), mean (SD)</th><th align="left" rowspan="1" colspan="1">Pre&#x02010;Endoflip CSA 50 (mm<sup>2</sup>), mean (SD)</th><th align="left" rowspan="1" colspan="1">Post G&#x02010;POEM Endoflip DI 30 (mm<sup>2</sup>/mmHg), mean (SD)</th><th align="left" rowspan="1" colspan="1">Post G&#x02010;POEM Endoflip DI 40 (mm<sup>2</sup>/mmHg), mean (SD)</th><th align="left" rowspan="1" colspan="1">Post G&#x02010;POEM Endoflip DI 50 (mm<sup>2</sup>/mmHg), mean (SD)</th><th align="left" rowspan="1" colspan="1">Post G&#x02010;POEM Endoflip CSA 30 (mm<sup>2</sup>), mean (SD)</th><th align="left" rowspan="1" colspan="1">Post G&#x02010;POEM Endoflip CSA 40 (mm<sup>2</sup>), mean (SD)</th><th align="left" rowspan="1" colspan="1">Post G&#x02010;POEM Endoflip CSA 50 (mm<sup>2</sup>), mean (SD)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Gregor et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">7.2 (3.9)</td><td align="left" rowspan="1" colspan="1">6.5 (2.5)</td><td align="left" rowspan="1" colspan="1">4.7 (1.7)</td><td align="left" rowspan="1" colspan="1">83</td><td align="left" rowspan="1" colspan="1">122</td><td align="left" rowspan="1" colspan="1">171.6</td><td align="left" rowspan="1" colspan="1">9.1 (3.8)</td><td align="left" rowspan="1" colspan="1">9.7 (2.3)</td><td align="left" rowspan="1" colspan="1">6.9 (1.8)</td><td align="left" rowspan="1" colspan="1">97.7</td><td align="left" rowspan="1" colspan="1">162.2</td><td align="left" rowspan="1" colspan="1">226.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Vosoughi et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">7.8 (4.9)</td><td align="left" rowspan="1" colspan="1">7.1 (3.7)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">119.1 (60.7)</td><td align="left" rowspan="1" colspan="1">176 (64.5)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">8.8 (6.1)</td><td align="left" rowspan="1" colspan="1">8.6 (6.1)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">146.5 (79)</td><td align="left" rowspan="1" colspan="1">206.9 (94.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Conchillo et&#x000a0;al.</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">5.3 med (3.1&#x02013;8.1)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">142.1 med (94.5&#x02013;155.2)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">7.5 (6.9&#x02013;11.7)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">159.2 (121.0&#x02013;187.6)</td><td align="left" rowspan="1" colspan="1">NA</td></tr></tbody></table><table-wrap-foot><fn id="deo270021-tbl5-note-0001"><p>Abbreviations: CSA, cross&#x02010;sectional area; DI Distensibility Index; NA, not available.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><sec id="deo270021-sec-0160"><title>Quality assessment</title><p>Table <xref rid="deo270021-supinfo-0001" ref-type="">S3</xref> shows the methodologic quality of included studies according to NOS assessment. Specifically, 6 studies were considered of good quality, five of fair quality, and two of poor quality.</p></sec><sec id="deo270021-sec-0170"><title>Publication bias</title><p>The rank correlation tests for the 1&#x02010;year and overall AEs revealed no significant publication bias (<italic toggle="yes">p</italic> = 0.45 and 0.31, respectively). Funnel plots are shown in Figures <xref rid="deo270021-supinfo-0001" ref-type="">S2 and S3</xref>.</p></sec><sec id="deo270021-sec-0180"><title>Clinical success at 1 year</title><p>Thirteen studies analyzed clinical success 1&#x02010;year post&#x02010;G&#x02010;POEM.<xref rid="deo270021-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="deo270021-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="deo270021-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="deo270021-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="deo270021-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="deo270021-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="deo270021-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="deo270021-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="deo270021-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="deo270021-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="deo270021-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>, <xref rid="deo270021-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> However, the study by Labonde et&#x000a0;al.<xref rid="deo270021-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> was not included in the analyses because it involved patients included in the cohort by Ragi et&#x000a0;al.<xref rid="deo270021-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>
</p><p>The pooled clinical success was 0.72 (95% CI: 0.56, 0.85, I<sup>2</sup> = 94.9%) as shown in Figure&#x000a0;<xref rid="deo270021-fig-0001" ref-type="fig">1</xref>. In LOO analyses, excluding the study by Tan et&#x000a0;al.<xref rid="deo270021-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> which only included patients with post&#x02010;surgical GP, the pooled 1&#x02010;year clinical success was 0.71 (95% CI: 0.55, 0.84; Figure <xref rid="deo270021-supinfo-0001" ref-type="">S4</xref>).</p><fig position="float" fig-type="FIGURE" id="deo270021-fig-0001"><label>FIGURE 1</label><caption><p>Pooled clinical success 1 year after gastric peroral endoscopic myotomy.</p></caption><graphic xlink:href="DEO2-5-e70021-g003" position="anchor" id="jats-graphic-1"/></fig><p>In the subgroup analysis that included only studies defining GP as 4 h PGR &#x02265; 10%, the pooled clinical success was 0.61 (95% CI: 0.52, 0.70, I<sup>2</sup> = 46.6%; Table <xref rid="deo270021-supinfo-0001" ref-type="">S4</xref>).</p><p>In the subgroup analysis that included only studies defining success as a 1&#x02010;point decrease of total GCSI score and at least 25% decrease of two GCSI subscales&#x02010; 4 studies,<xref rid="deo270021-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="deo270021-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="deo270021-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="deo270021-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> the pooled clinical success was 0.67 (95% CI: 0.47, 0.97, I<sup>2</sup> = 95.8%; Table <xref rid="deo270021-supinfo-0001" ref-type="">S4</xref>).</p></sec><sec id="deo270021-sec-0190"><title>Clinical success at 2 and 3 years</title><p>Clinical success 2 years post&#x02010;G&#x02010;POEM was reported in five studies.<xref rid="deo270021-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="deo270021-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="deo270021-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="deo270021-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="deo270021-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> The pooled clinical success was 0.71 (95% CI: 0.45, 0.92, I<sup>2</sup> = 94.9%) as shown in Figure&#x000a0;<xref rid="deo270021-fig-0002" ref-type="fig">2</xref>. Clinical success at 3 years was assessed in three studies with reported 1&#x02010;year outcomes.<xref rid="deo270021-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="deo270021-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="deo270021-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> The pooled clinical success was 0.58 (95% CI: 0.19, 0.92, I<sup>2</sup> = 97.1%; Figure&#x000a0;<xref rid="deo270021-fig-0003" ref-type="fig">3</xref>).</p><fig position="float" fig-type="FIGURE" id="deo270021-fig-0002"><label>FIGURE 2</label><caption><p>Pooled clinical success 2 years after gastric peroral endoscopic myotomy for patients who experienced success after the first year.</p></caption><graphic xlink:href="DEO2-5-e70021-g001" position="anchor" id="jats-graphic-3"/></fig><fig position="float" fig-type="FIGURE" id="deo270021-fig-0003"><label>FIGURE 3</label><caption><p>Pooled clinical success 2 years after gastric peroral endoscopic myotomy for patients who experienced success after the first year.</p></caption><graphic xlink:href="DEO2-5-e70021-g002" position="anchor" id="jats-graphic-5"/></fig></sec><sec id="deo270021-sec-0200"><title>GCSI score changes</title><p>The pooled mean GCSI scores before the procedure, 1&#x02010;year post&#x02010;G&#x02010;POEM, and 2 years post&#x02010;G&#x02010;POEM are shown in Table <xref rid="deo270021-supinfo-0001" ref-type="">S4</xref>. The MD between the 1&#x02010;year post&#x02010;procedure and pre&#x02010;operative GCSI was &#x02212;1.61 (95% CI: &#x02212;2.18, &#x02212;1.04, I<sup>2</sup> = 98.6%). The MD between 2 years&#x02019; post&#x02010;procedure and pre&#x02010;operative GCSI was &#x02212;2.18 (95% CI: &#x02212;2.25, &#x02212;2.12, I<sup>2</sup> = 0%; Table <xref rid="deo270021-supinfo-0001" ref-type="">S4</xref>).</p></sec><sec id="deo270021-sec-0210"><title>GES parameters</title><p>The pooled mean gastric half&#x02010;emptying time (t &#x000bd;) and 4&#x02010;h PGR scores before and after the procedure are presented in Table <xref rid="deo270021-supinfo-0001" ref-type="">S4</xref>. The pooled MD in gastric half time between pre&#x02010;operative and post&#x02010;operative assessment was &#x02212;106.82 min (95% CI: &#x02212;183.285, &#x02212;30.363.73, 8.48, I<sup>2</sup> = 98.8%). The pooled MD in 4&#x02010;h PGR between pre&#x02010;operative and post&#x02010;operative assessment was &#x02212;27.3 (95% CI: &#x02212;34.5, &#x02212;20.0, I<sup>2</sup> = 68.1%; Table <xref rid="deo270021-supinfo-0001" ref-type="">S4</xref>).</p></sec><sec id="deo270021-sec-0220"><title>Adverse events</title><p>Data on AEs were provided by 12 studies.<xref rid="deo270021-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="deo270021-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="deo270021-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="deo270021-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="deo270021-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="deo270021-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="deo270021-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="deo270021-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="deo270021-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="deo270021-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="deo270021-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>, <xref rid="deo270021-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> The pooled rate of AEs was 0.08 (95% CI: 0.06, 0.10, I<sup>2</sup> = 0%) as shown in Figure&#x000a0;<xref rid="deo270021-fig-0004" ref-type="fig">4</xref>). AEs according to the American Society for Gastrointestinal Endoscopy (ASGE) and detailed events are presented in Tables&#x000a0;<xref rid="deo270021-tbl-0003" ref-type="table">3</xref> and&#x000a0;<xref rid="deo270021-tbl-0004" ref-type="table">4</xref>. The pooled rates for mild, moderate, and severe AEs were 0.06 (95% CI: 0.05, 0.08, I<sup>2</sup> = 0%), 0.01 (95% CI: 0.00, 0.02, I<sup>2</sup> = 0%), and 0.00 (95% CI: 0.00, 0.01 I<sup>2</sup> = 0%), as presented in Table <xref rid="deo270021-supinfo-0001" ref-type="">S4</xref>.</p><fig position="float" fig-type="FIGURE" id="deo270021-fig-0004"><label>FIGURE 4</label><caption><p>Pooled rate of overall adverse events.</p></caption><graphic xlink:href="DEO2-5-e70021-g004" position="anchor" id="jats-graphic-7"/></fig></sec><sec id="deo270021-sec-0230"><title>Endoflip</title><p>Three studies provided EndoFLIP measurements in both pre&#x02010; and post&#x02010;G&#x02010;POEM procedures.<xref rid="deo270021-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="deo270021-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="deo270021-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> In all three studies, an increase in the Distensibility Index (DI) post&#x02010;G&#x02010;POEM was observed. Additionally, the study by Gregor et&#x000a0;al. reported an increase in the post&#x02010;myotomy cross&#x02010;sectional area (CSA).<xref rid="deo270021-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> Further details are provided in Table&#x000a0;<xref rid="deo270021-tbl-0005" ref-type="table">5</xref>.</p></sec><sec id="deo270021-sec-0240"><title>Factors of predictive success and failure</title><p>In the study by Hernandez Mondragon et&#x000a0;al., predictors of success included diabetic etiology, early diagnosis within 24 months, predominant symptoms of nausea and vomiting, and GCSI scores between 1.5 and 2.5 at 6 months.<xref rid="deo270021-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> Vosoughi et&#x000a0;al. found that CSA at 40&#x02010;mL (&#x0003e;154 mm<sup>2</sup>) and 50&#x02010;mL (&#x0003e;247.5 mm<sup>2</sup>) distention volumes at post&#x02010;G&#x02010;POEM EndoFLIP were associated with clinical success.<xref rid="deo270021-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> Ragi et&#x000a0;al. reported that high pre&#x02010;operative GCSI satiety subscale scores were predictors of success.<xref rid="deo270021-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> Conversely, Abdelfatah et&#x000a0;al. found that a higher BMI, the use of psychiatric and pain medications, a longer duration of GP, and higher pre&#x02010;operative nausea were associated with unfavorable outcomes (Table <xref rid="deo270021-supinfo-0001" ref-type="">S5</xref>).<xref rid="deo270021-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>
</p></sec></sec><sec id="deo270021-sec-0250"><title>DISCUSSION</title><p>This meta&#x02010;analysis shows that the 1&#x02010;year clinical success of G&#x02010;POEM across 13 studies was equal to 72% (I<sup>2</sup> = 94.9%). Consistent results were found when adopting only the most recent definition of success,<xref rid="deo270021-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> with pooled 1&#x02010;year clinical success equal to 67.7% (I<sup>2 =</sup> 95.85%). The substantial heterogeneity reflects the variability among the studies included in the meta&#x02010;analysis and arises from differences in study design, population characteristics, and success definition. To address this issue, we conducted subgroup analyses, which partially reduced the level of heterogeneity. When considering only studies enrolling patients with 4&#x02010;h PGR &#x0003e; 10%, the clinical success was slightly lower and equal to 61.0%, with I<sup>2</sup> = 46.6%). The reduction of clinical success rate and heterogeneity may be interpreted as being due to a more accurate selection of patients with GP.</p><p>Our 1&#x02010;year clinical success after G&#x02010;POEM is similar to the short&#x02010;term success reported in the randomized controlled trial by Martinek and colleagues and in the previous meta&#x02010;analyses by Mohan et&#x000a0;al., ranging from 71% to 75.8%.<xref rid="deo270021-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="deo270021-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> Remarkably, it is higher than the 1&#x02010;year pooled clinical success of 61% reported in the meta&#x02010;analysis by Kamal et&#x000a0;al., published in 2021.<xref rid="deo270021-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> This might be due to evolving methodologies and increasing knowledge on GP, potentially leading to improved pooled success after G&#x02010;POEM.</p><p>According to our pooled estimates, G&#x02010;POEM maintained clinical efficacy for 71% of patients at 2 years and 58% at 3 years, who had achieved 1&#x02010;year clinical success. Our data suggest that G&#x02010;POEM may have a lasting clinical efficacy even beyond 1 year, albeit gradually diminishing over time.</p><p>Comprehensive long&#x02010;term data on G&#x02010;POEM are scarce. Only a recent meta&#x02010;analysis conducted by Canakis et&#x000a0;al. analyzed the outcomes of G&#x02010;POEM beyond 3 years, reporting a clinical success of 75%. However, in the pooled analysis, the authors utilized the number of followed&#x02010;up patients from the initial cohort as the denominator, not considering patients with no follow&#x02010;up as clinical failures across all included studies. This approach could have potentially influenced the results.<xref rid="deo270021-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>
</p><p>One of the critical issues with G&#x02010;POEM is identifying patients with refractory GP who could benefit from the procedure. In our systematic review, we analyzed predictive factors for the success of myotomy reported in long&#x02010;term studies. Factors such as GCSI &#x0003e;2.6 and clinical success at 1 month have been reported as predictors of clinical success at 12 months.<xref rid="deo270021-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> High BMI, long duration of GP, and psychiatric or narcotic medication use have been associated with poor outcomes.<xref rid="deo270021-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> However, at present, the outcome predictors of myotomy appear to be inconsistent and somewhat contradictory. For example, factors such as predominant nausea or a high 4&#x02010;h PGR have been identified as both a success factor,<xref rid="deo270021-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="deo270021-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> and a failure factor.<xref rid="deo270021-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="deo270021-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> These conflicting results make it challenging to establish clear guidelines for predicting outcomes. Currently, the evidence remains weak, and unfortunately, the implications for clinical practice are merely suggestive at this time. This highlights the need for further research to better define the predictors of success for G&#x02010;POEM and to standardize criteria for patient selection.</p><p>In recent years, new advancements like GES regional analysis and EndoFLIP, have emerged as techniques to identify GP patients who could benefit from pyloromyotomy. In a prospective study conducted by our group, lower median pre&#x02010;procedural Intragastric Meal Distribution at time 0 (indicating impaired fundic accommodation) was found to correlate with a higher G&#x02010;POEM success rate.<xref rid="deo270021-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> Endoflip is a promising tool for identifying appropriate GP patients for G&#x02010;POEM in the realm of precision endoscopy.<xref rid="deo270021-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> In the study conducted by Jacques et&#x000a0;al., a preoperative EndoFLIP pylorus DI threshold of 9.2 mm<sup>2</sup>/mmHg was found to predict G&#x02010;POEM success with 72% sensitivity and 100% specificity.<xref rid="deo270021-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> In our systematic review all studies analyzing the use of EndoFLIP showed an improved pyloric DI and an increase in CSA after G&#x02010;POEM. This suggests that the myotomy effectively alters pyloric function. However, this does not incontrovertibly correlate with symptom improvement. GP is a complex disease with multiple pathophysiological mechanisms contributing to GE impairment, which include, in addition to pylorospasm, impaired gastric accommodation, and antro&#x02010;duodenal dysmotility.<xref rid="deo270021-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> The impact of these mechanisms on symptoms, still partially unknown, can vary, and it is plausible that not all may be addressed with pyloromyotomy. Further research is needed to better define the association between the organic change of the pyloric muscle after G&#x02010;POEM and symptom relief, as well as the role of EndoFLIP in myotomy patient selection.</p><p>The definition of post&#x02010;G&#x02010;POEM clinical success poses an additional challenge. Primarily, success following G&#x02010;POEM is evaluated using the GCSI score. However, this score might not be entirely suitable as it includes the assessment of non&#x02010;specific gastrointestinal symptoms that are also present in other functional diseases. Moreover, the arbitrary nature of the most recent definition of success<xref rid="deo270021-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> raises questions about its clinical significance and validity. Nevertheless, it is important to note that the improvement of symptomatology remains the primary G&#x02010;POEM outcome, especially considering that GES has not been shown to correlate with GP symptoms.<xref rid="deo270021-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref> In this regard, our meta&#x02010;analysis shows long&#x02010;term improvements in the GCSI following G&#x02010;POEM, with an MD of &#x02212;1.61 at 1 year and &#x02212;2.18 at 2 years compared to the pre&#x02010;treatment score. Additionally, we found significant post&#x02010;operative improvements in GES parameters compared to the pre&#x02010;treatment (MD of t &#x000bd; &#x02212;97.62 min and a 4&#x02010;h PGR reduction of &#x02212;27.32). Collectively, our findings show that G&#x02010;POEM leads to clinical and functional improvements.</p><p>In our meta&#x02010;analysis, the pooled rate of AEs was 8.4% (6.9% mild and 1.5% moderate, according to the ASGE classification).<xref rid="deo270021-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> This rate is similar to the 8% reported in the meta&#x02010;analysis by Kamal et&#x000a0;al.<xref rid="deo270021-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> Predominantly, AEs included bleeding/post&#x02010;myotomy ulcers (28 cases) and mucosotomy/leak (19 cases). Our data confirm that G&#x02010;POEM is a safe procedure, with very rare occurrences of severe AEs.</p><p>Our meta&#x02010;analysis is not without limitations. The pooled estimates in our analysis carry a moderate to high heterogeneity. As mentioned earlier, these mostly arise from methodological issues in existing long&#x02010;term studies on G&#x02010;POEM. Long&#x02010;term G&#x02010;POEM studies exhibit inconsistencies in defining clinical success and have varying follow&#x02010;up durations, which present significant challenges for conducting pooled analyses. However, to minimize this limitation, we performed a subgroup analysis including only studies that adopted the most recent definition of clinical success.<xref rid="deo270021-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>
</p><p>In addition to the high heterogeneity, the relatively wide range of 95% CI is also a limitation of this study. The wide CIs reflect greater uncertainty about the estimated effect size, likely due to variability between studies and small sample sizes, especially in some of the included studies. This suggests that the true effect may vary, making it harder to draw definitive conclusions about the effect size. Therefore, caution should be exercised in interpreting the results.</p><p>Another concern is that in some studies not all patients from the initial cohort were followed up at 2 and 3 years. However, in calculating the pooled clinical success at 2&#x02013;3 years, we have considered only the number of patients with clinical success at 12 months as the denominator. In our view, this analysis represents the most reliable method for estimating success at 2 and 3 years based on current studies.</p><p>Despite the limitations of the included studies, our meta&#x02010;analysis represents the most comprehensive summary of 1&#x02010;year clinical success of G&#x02010;POEM in nearly 1000 patients. It also presents pooled success data beyond 1 year in over 600 patients. Our results demonstrate that G&#x02010;POEM achieves clinical success at 1 year in approximately 70% of patients, which may be sustained but could decline over time. As we await new studies to clarify the pathogenesis of GP, there is an urgent need for standardized measures to facilitate the interpretation of G&#x02010;POEM outcomes.</p></sec><sec sec-type="COI-statement" id="deo270021-sec-0260"><title>CONFLICT OF INTEREST STATEMENT</title><p>None.</p></sec><sec id="deo270021-sec-0270"><title>ETHICS STATEMENT</title><p>
<list list-type="bullet" id="deo270021-list-0001"><list-item><p>
<bold>Approval of the research protocol by an Institutional Reviewer Board</bold>: N/A</p></list-item><list-item><p>
<bold>Informed Consent</bold>: N/A</p></list-item><list-item><p>
<bold>Registry and registration no. of the study</bold>: Prospective Register of Systematic Reviews (PROSPERO) (ID: CRD42022369842).</p></list-item><list-item><p>
<bold>Animal studies</bold>: N/A</p></list-item></list>
</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="deo270021-supinfo-0001" position="float" content-type="local-data"/><supplementary-material id="deo270021-supitem-0001" position="float" content-type="local-data"><caption><p>
<bold>Table S1</bold> Preferred Reporting Items for Systematic Reviews and Meta&#x02010;Analyses (PRISMA) checklist.</p><p>
<bold>Table S2</bold> Detailed search strategy for systematic review.</p><p>
<bold>Table S3</bold> Newcastle Ottawa Scale (NOS) assessment for Cohort studies.</p><p>
<bold>Table S4</bold> Pooled analysis of 1&#x02010;year subgroup clinical success, Gastroparesis Cardinal Symptom Index (GCSI) score, Gastric Emptying Study (GES) parameters, and adverse events subgrouped by severity.</p><p>
<bold>Table S5</bold> Factors predicting Gastric Peroral Endoscopic Myotomy (G&#x02010;POEM) success or failure.</p><p>
<bold>Figure S1</bold> Flow diagram of study selection according to the Preferred Reporting Items for Systematic Reviews and Meta&#x02010;analyses.</p><p>
<bold>Figure S2</bold> Funnel plot for 1 year&#x02010;clinical success.</p><p>
<bold>Figure S3</bold> Funnel plot for overall adverse events rate.</p><p>
<bold>Figure S4</bold> Leave&#x02010;One&#x02010;Out (LOO) sensitivity analyses for pooled clinical success 1 year after Gastric Peroral Endoscopic Myotomy (G&#x02010;POEM).</p></caption><media xlink:href="DEO2-5-e70021-s001.docx"/></supplementary-material></sec></body><back><ref-list id="deo270021-bibl-0001"><title>REFERENCES</title><ref id="deo270021-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="deo270021-cit-0001">
<string-name>
<surname>Camilleri</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Chedid</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Ford</surname>
<given-names>AC</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Gastroparesis</article-title>. <source>Nat Rev Dis Primers</source>
<year>2018</year>; <volume>4</volume>: <fpage>41</fpage>.<pub-id pub-id-type="pmid">30385743</pub-id>
</mixed-citation></ref><ref id="deo270021-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="deo270021-cit-0002">
<string-name>
<surname>Wadhwa</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Mehta</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Jobanputra</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Lopez</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Thota</surname>
<given-names>PN</given-names>
</string-name>, <string-name>
<surname>Sanaka</surname>
<given-names>MR</given-names>
</string-name>. <article-title>Healthcare utilization and costs associated with gastroparesis</article-title>. <source>World J Gastroenterol</source>
<year>2017</year>; <volume>23</volume>: <fpage>4428</fpage>&#x02013;44<lpage>36</lpage>.<pub-id pub-id-type="pmid">28706426</pub-id>
</mixed-citation></ref><ref id="deo270021-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="deo270021-cit-0003">
<string-name>
<surname>Mandarino</surname>
<given-names>FV</given-names>
</string-name>, <string-name>
<surname>Sinagra</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Barchi</surname>
<given-names>A</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Gastroparesis: The complex interplay with microbiota and the role of exogenous infections in the pathogenesis of the disease</article-title>. <source>Microorganisms</source>
<year>2023</year>; <volume>11</volume>: <fpage>1122</fpage>.<pub-id pub-id-type="pmid">37317096</pub-id>
</mixed-citation></ref><ref id="deo270021-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="deo270021-cit-0004">
<string-name>
<surname>Ezzeddine</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Jit</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Katz</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Gopalswamy</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Bhutani</surname>
<given-names>MS</given-names>
</string-name>. <article-title>Pyloric injection of botulinum toxin for treatment of diabetic gastroparesis</article-title>. <source>Gastrointest Endosc</source>
<year>2002</year>; <volume>55</volume>: <fpage>920</fpage>&#x02013;92<lpage>3</lpage>.<pub-id pub-id-type="pmid">12024156</pub-id>
</mixed-citation></ref><ref id="deo270021-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="deo270021-cit-0005">
<string-name>
<surname>Wellington</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Scott</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Kundu</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Stuart</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Koch</surname>
<given-names>KL</given-names>
</string-name>. <article-title>Effect of endoscopic pyloric therapies for patients with nausea and vomiting and functional obstructive gastroparesis</article-title>. <source>Auton Neurosci</source>
<year>2017</year>; <volume>202</volume>: <fpage>56</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">27460691</pub-id>
</mixed-citation></ref><ref id="deo270021-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="deo270021-cit-0006">
<string-name>
<surname>Pioppo</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Reja</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Gaidhane</surname>
<given-names>M</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Gastric per&#x02010;oral endoscopic myotomy versus pyloromyotomy for gastroparesis: An international comparative study</article-title>. <source>J Gastroenterol Hepatol</source>
<year>2021</year>; <volume>36</volume>: <fpage>3177</fpage>&#x02013;<lpage>3182</lpage>.<pub-id pub-id-type="pmid">34170565</pub-id>
</mixed-citation></ref><ref id="deo270021-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="deo270021-cit-0007">
<string-name>
<surname>Martinek</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hustak</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Mares</surname>
<given-names>J</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Endoscopic pyloromyotomy for the treatment of severe and refractory gastroparesis: A pilot, randomised, sham&#x02010;controlled trial</article-title>. <source>Gut</source>
<year>2022</year>; <volume>71</volume>: <fpage>2170</fpage>&#x02013;<lpage>2178</lpage>.<pub-id pub-id-type="pmid">35470243</pub-id>
</mixed-citation></ref><ref id="deo270021-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="deo270021-cit-0008">
<string-name>
<surname>Moher</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Liberati</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Tetzlaff</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Altman</surname>
<given-names>DG</given-names>
</string-name>; <collab collab-type="authors">PRISMA Group</collab>
. <article-title>Preferred reporting items for systematic reviews and meta&#x02010;analyses: The PRISMA Statement</article-title>. <source>Open Med</source>
<year>2009</year>; <volume>3</volume>: <fpage>e123</fpage>&#x02013;<lpage>e130</lpage>.<pub-id pub-id-type="pmid">21603045</pub-id>
</mixed-citation></ref><ref id="deo270021-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="deo270021-cit-0009">
<string-name>
<surname>Revicki</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Rentz</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Dubois</surname>
<given-names>D</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Gastroparesis Cardinal Symptom Index (GCSI): Development and validation of a patient reported assessment of severity of gastroparesis symptoms</article-title>. <source>Qual Life Res</source>
<year>2004</year>; <volume>13</volume>: <fpage>833</fpage>&#x02013;<lpage>844</lpage>.<pub-id pub-id-type="pmid">15129893</pub-id>
</mixed-citation></ref><ref id="deo270021-bib-0010"><label>10</label><mixed-citation publication-type="miscellaneous" id="deo270021-cit-0010">
<string-name>
<surname>Wells</surname>
<given-names>GA</given-names>
</string-name>, <string-name>
<surname>Shea</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>O'Connell</surname>
<given-names>D</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>The Newcastle&#x02010;Ottawa Scale (NOS) for assessing the quality of non randomised studies in meta analysis</article-title>. <year>2014</year>. Available from: <ext-link xlink:href="http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp" ext-link-type="uri">http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp</ext-link>
</mixed-citation></ref><ref id="deo270021-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="deo270021-cit-0011">
<string-name>
<surname>Vosoughi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ichkhanian</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Benias</surname>
<given-names>P</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Gastric per&#x02010;oral endoscopic myotomy (G&#x02010;POEM) for refractory gastroparesis: Results from an international prospective trial</article-title>. <source>Gut</source>
<year>2022</year>; <volume>71</volume>: <fpage>25</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">33741641</pub-id>
</mixed-citation></ref><ref id="deo270021-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="deo270021-cit-0012">
<string-name>
<surname>Cotton</surname>
<given-names>PB</given-names>
</string-name>, <string-name>
<surname>Eisen</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Aabakken</surname>
<given-names>L</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>A lexicon for endoscopic adverse events: Report of an ASGE workshop</article-title>. <source>Gastrointest Endosc</source>
<year>2010</year>; <volume>71</volume>: <fpage>446</fpage>&#x02013;<lpage>454</lpage>.<pub-id pub-id-type="pmid">20189503</pub-id>
</mixed-citation></ref><ref id="deo270021-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="deo270021-cit-0013">
<string-name>
<surname>Hozo</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Djulbegovic</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Hozo</surname>
<given-names>I</given-names>
</string-name>. <article-title>Estimating the mean and variance from the median, range, and the size of a sample</article-title>. <source>BMC Med Res Methodol</source>
<year>2005</year>; <volume>5</volume>: <fpage>13</fpage>.<pub-id pub-id-type="pmid">15840177</pub-id>
</mixed-citation></ref><ref id="deo270021-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="deo270021-cit-0014">
<string-name>
<surname>Shi</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Luo</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Weng</surname>
<given-names>H</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Optimally estimating the sample standard deviation from the five&#x02010;number summary</article-title>. <source>Res Synth Methods</source>
<year>2020</year>; <volume>11</volume>: <fpage>641</fpage>&#x02013;<lpage>654</lpage>.<pub-id pub-id-type="pmid">32562361</pub-id>
</mixed-citation></ref><ref id="deo270021-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="deo270021-cit-0015">
<string-name>
<surname>Luo</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Wan</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Tong</surname>
<given-names>T</given-names>
</string-name>. <article-title>Optimally estimating the sample mean from the sample size, median, mid&#x02010;range, and/or mid&#x02010;quartile range</article-title>. <source>Stat Methods Med Res</source>
<year>2018</year>; <volume>27</volume>: <fpage>1785</fpage>&#x02013;<lpage>1805</lpage>.<pub-id pub-id-type="pmid">27683581</pub-id>
</mixed-citation></ref><ref id="deo270021-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="deo270021-cit-0016">
<string-name>
<surname>Wan</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Tong</surname>
<given-names>T</given-names>
</string-name>. <article-title>Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range</article-title>. <source>BMC Med Res Methodol</source>
<year>2014</year>; <volume>14</volume>: <fpage>135</fpage>.<pub-id pub-id-type="pmid">25524443</pub-id>
</mixed-citation></ref><ref id="deo270021-bib-0017"><label>17</label><mixed-citation publication-type="book" id="deo270021-cit-0017">
<string-name>
<surname>Higgins</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Thomas</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Chandler</surname>
<given-names>J</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<source>Cochrane Handbook for Systematic Reviews of Interventions version 6.4</source>, <publisher-loc>Ontario</publisher-loc>: <publisher-name>Cochrane</publisher-name>, <year>2023</year>. Available from: <ext-link xlink:href="http://www.training.cochrane.org/handbook" ext-link-type="uri">http://www.training.cochrane.org/handbook</ext-link>
</mixed-citation></ref><ref id="deo270021-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="deo270021-cit-0018">
<string-name>
<surname>Abdelfatah</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Noll</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kapil</surname>
<given-names>N</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Long&#x02010;term outcome of gastric per&#x02010;oral endoscopic pyloromyotomy in treatment of gastroparesis</article-title>. <source>Clin Gastroenterol Hepatol</source>
<year>2021</year>; <volume>19</volume>: <fpage>816</fpage>&#x02013;<lpage>824</lpage>.<pub-id pub-id-type="pmid">32450364</pub-id>
</mixed-citation></ref><ref id="deo270021-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="deo270021-cit-0019">
<string-name>
<surname>Gregor</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Wo</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>DeWitt</surname>
<given-names>J</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Gastric peroral endoscopic myotomy for the treatment of refractory gastroparesis: A prospective single&#x02010;center experience with mid&#x02010;term follow&#x02010;up (with video)</article-title>. <source>Gastrointest Endosc</source>
<year>2021</year>; <volume>94</volume>: <fpage>35</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">33373646</pub-id>
</mixed-citation></ref><ref id="deo270021-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="deo270021-cit-0020">
<string-name>
<surname>Hern&#x000e1;ndez Mondrag&#x000f3;n</surname>
<given-names>OV</given-names>
</string-name>, <string-name>
<surname>Contreras</surname>
<given-names>LFG</given-names>
</string-name>, <string-name>
<surname>Velasco</surname>
<given-names>GB</given-names>
</string-name>, <string-name>
<surname>Pineda</surname>
<given-names>OMS</given-names>
</string-name>, <string-name>
<surname>Carrillo</surname>
<given-names>DMC</given-names>
</string-name>, <string-name>
<surname>Perez</surname>
<given-names>EM</given-names>
</string-name>. <article-title>Gastric peroral endoscopic myotomy outcomes after 4 years of follow&#x02010;up in a large cohort of patients with refractory gastroparesis (with video)</article-title>. <source>Gastrointest Endosc</source>
<year>2022</year>; <volume>96</volume>: <fpage>487</fpage>&#x02013;<lpage>499</lpage>.<pub-id pub-id-type="pmid">35378136</pub-id>
</mixed-citation></ref><ref id="deo270021-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="deo270021-cit-0021">
<string-name>
<surname>Hustak</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Vackov&#x000e1;</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Krajciova</surname>
<given-names>J</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Per&#x02010;oral endoscopic pyloromyotomy (G&#x02010;POEM) for the treatment of gastroparesis &#x02013; A pilot single&#x02010;centre study with mid&#x02010;term follow&#x02010;up</article-title>. <source>Rozhl Chir</source>
<year>2020</year>; <volume>99</volume>: <fpage>116</fpage>&#x02013;<lpage>123</lpage>.<pub-id pub-id-type="pmid">32349495</pub-id>
</mixed-citation></ref><ref id="deo270021-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="deo270021-cit-0022">
<string-name>
<surname>Labonde</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lades</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Debourdeau</surname>
<given-names>A</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Gastric peroral endoscopic myotomy in refractory gastroparesis: Long&#x02010;term outcomes and predictive score to improve patient selection</article-title>. <source>Gastrointest Endosc</source>
<year>2022</year>; <volume>96</volume>: <fpage>500</fpage>&#x02013;<lpage>508</lpage>.e2.<pub-id pub-id-type="pmid">35413333</pub-id>
</mixed-citation></ref><ref id="deo270021-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="deo270021-cit-0023">
<string-name>
<surname>Tan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Shrestha</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Wei</surname>
<given-names>M</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Feasibility, safety, and long&#x02010;term efficacy of gastric peroral endoscopic myotomy (G&#x02010;POEM) for postsurgical gastroparesis: A single&#x02010;center and retrospective study of a prospective database</article-title>. <source>Surg Endosc</source>
<year>2021</year>; <volume>35</volume>: <fpage>3459</fpage>&#x02013;<lpage>3470</lpage>.<pub-id pub-id-type="pmid">32880749</pub-id>
</mixed-citation></ref><ref id="deo270021-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="deo270021-cit-0024">
<string-name>
<surname>Vosoughi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ichkhanian</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Jacques</surname>
<given-names>J</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Role of endoscopic functional luminal imaging probe in predicting the outcome of gastric peroral endoscopic pyloromyotomy (with video)</article-title>. <source>Gastrointest Endosc</source>
<year>2020</year>; <volume>91</volume>: <fpage>1289</fpage>&#x02013;<lpage>1299</lpage>.<pub-id pub-id-type="pmid">32035074</pub-id>
</mixed-citation></ref><ref id="deo270021-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="deo270021-cit-0025">
<string-name>
<surname>Ragi</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Jacques</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Branche</surname>
<given-names>J</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>One&#x02010;year results of gastric peroral endoscopic myotomy for refractory gastroparesis: A French multicenter study</article-title>. <source>Endoscopy</source>
<year>2021</year>; <volume>53</volume>: <fpage>480</fpage>&#x02013;<lpage>490</lpage>.<pub-id pub-id-type="pmid">32575130</pub-id>
</mixed-citation></ref><ref id="deo270021-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="deo270021-cit-0026">
<string-name>
<surname>Xu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Elkholy</surname>
<given-names>S</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Gastric peroral endoscopic myotomy (G&#x02010;POEM) as a treatment for refractory gastroparesis: Long&#x02010;term outcomes</article-title>. <source>Can J Gastroenterol Hepatol</source>
<year>2018</year>; <volume>2018</volume>: <elocation-id>6409698</elocation-id>.<pub-id pub-id-type="pmid">30425974</pub-id>
</mixed-citation></ref><ref id="deo270021-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="deo270021-cit-0027">
<string-name>
<surname>Kahaleh</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gonzalez</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>MM</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Gastric peroral endoscopic myotomy for the treatment of refractory gastroparesis: A multicenter international experience</article-title>. <source>Endoscopy</source>
<year>2018</year>; <volume>50</volume>: <fpage>1053</fpage>&#x02013;<lpage>1058</lpage>.<pub-id pub-id-type="pmid">29649841</pub-id>
</mixed-citation></ref><ref id="deo270021-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="deo270021-cit-0028">
<string-name>
<surname>Reja</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mishra</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Tyberg</surname>
<given-names>A</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Gastric peroral endoscopic myotomy: A specific learning curve</article-title>. <source>J Clin Gastroenterol</source>
<year>2022</year>; <volume>56</volume>: <fpage>339</fpage>&#x02013;<lpage>342</lpage>.<pub-id pub-id-type="pmid">34009842</pub-id>
</mixed-citation></ref><ref id="deo270021-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="deo270021-cit-0029">
<string-name>
<surname>Conchillo</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Straathof</surname>
<given-names>JWA</given-names>
</string-name>, <string-name>
<surname>Mujagic</surname>
<given-names>Z</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Gastric peroral endoscopic pyloromyotomy for decompensated gastroparesis: Comprehensive motility analysis in relation to treatment outcomes</article-title>. <source>Endosc Int Open</source>
<year>2021</year>; <volume>9</volume>: <fpage>E137</fpage>&#x02013;<lpage>E144</lpage>.<pub-id pub-id-type="pmid">33532550</pub-id>
</mixed-citation></ref><ref id="deo270021-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="deo270021-cit-0030">
<string-name>
<surname>Mohan</surname>
<given-names>BP</given-names>
</string-name>, <string-name>
<surname>Chandan</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Jha</surname>
<given-names>LK</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Clinical efficacy of gastric per&#x02010;oral endoscopic myotomy (G&#x02010;POEM) in the treatment of refractory gastroparesis and predictors of outcomes: A systematic review and meta&#x02010;analysis using surgical pyloroplasty as a comparator group</article-title>. <source>Surg Endosc</source>
<year>2020</year>; <volume>34</volume>: <fpage>3352</fpage>&#x02013;<lpage>3367</lpage>.<pub-id pub-id-type="pmid">31583465</pub-id>
</mixed-citation></ref><ref id="deo270021-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="deo270021-cit-0031">
<string-name>
<surname>Kamal</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Khan</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Lee&#x02010;Smith</surname>
<given-names>W</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Systematic review with meta&#x02010;analysis: One&#x02010;year outcomes of gastric peroral endoscopic myotomy for refractory gastroparesis</article-title>. <source>Aliment Pharmacol Ther</source>
<year>2022</year>; <volume>55</volume>: <fpage>168</fpage>&#x02013;<lpage>177</lpage>.<pub-id pub-id-type="pmid">34854102</pub-id>
</mixed-citation></ref><ref id="deo270021-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="deo270021-cit-0032">
<string-name>
<surname>Canakis</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Deliwala</surname>
<given-names>SS</given-names>
</string-name>, <string-name>
<surname>Frohlinger</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Canakis</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Adler</surname>
<given-names>DG</given-names>
</string-name>. <article-title>Long&#x02010;term outcomes (&#x02265;3 years) after gastric peroral endoscopic myotomy for refractory gastroparesis: A systematic review and meta&#x02010;analysis</article-title>. <source>iGIE</source>
<year>2023</year>; <volume>2</volume>: <fpage>344</fpage>&#x02013;<lpage>349</lpage>.e3</mixed-citation></ref><ref id="deo270021-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="deo270021-cit-0033">
<string-name>
<surname>Mandarino</surname>
<given-names>FV</given-names>
</string-name>, <string-name>
<surname>Testoni</surname>
<given-names>SGG</given-names>
</string-name>, <string-name>
<surname>Barchi</surname>
<given-names>A</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Gastric emptying study before gastric peroral endoscopic myotomy (G&#x02010;POEM): Can intragastric meal distribution be a predictor of success?</article-title>
<source>Gut</source>
<year>2023</year>; <volume>72</volume>: <fpage>1019</fpage>&#x02013;<lpage>1020</lpage>.<pub-id pub-id-type="pmid">35697421</pub-id>
</mixed-citation></ref><ref id="deo270021-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="deo270021-cit-0034">
<string-name>
<surname>Mandarino</surname>
<given-names>FV</given-names>
</string-name>, <string-name>
<surname>Vespa</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Barchi</surname>
<given-names>A</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Precision endoscopy in peroral myotomies for motility disorders of the upper gastrointestinal tract: Current insights and prospective avenues&#x02013;A comprehensive review</article-title>. <source>Life</source>
<year>2023</year>; <volume>13</volume>: <fpage>2143</fpage>
<pub-id pub-id-type="pmid">38004283</pub-id>
</mixed-citation></ref><ref id="deo270021-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="deo270021-cit-0035">
<string-name>
<surname>Jacques</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Pagnon</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Hure</surname>
<given-names>F</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Peroral endoscopic pyloromyotomy is efficacious and safe for refractory gastroparesis: Prospective trial with assessment of pyloric function</article-title>. <source>Endoscopy</source>
<year>2019</year>; <volume>51</volume>: <fpage>40</fpage>&#x02013;<lpage>49</lpage>.<pub-id pub-id-type="pmid">29895073</pub-id>
</mixed-citation></ref><ref id="deo270021-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="deo270021-cit-0036">
<string-name>
<surname>Camilleri</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sanders</surname>
<given-names>KM</given-names>
</string-name>. <article-title>Opiates, the pylorus, and gastroparesis</article-title>. <source>Gastroenterology</source>
<year>2020</year>; <volume>159</volume>: <fpage>414</fpage>&#x02013;<lpage>421</lpage>.<pub-id pub-id-type="pmid">32389662</pub-id>
</mixed-citation></ref><ref id="deo270021-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="deo270021-cit-0037">
<string-name>
<surname>Mandarino</surname>
<given-names>FV</given-names>
</string-name>, <string-name>
<surname>Testoni</surname>
<given-names>SGG</given-names>
</string-name>, <string-name>
<surname>Barchi</surname>
<given-names>A</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Imaging in gastroparesis: Exploring innovative diagnostic approaches, symptoms, and treatment</article-title>. <source>Life</source>
<year>2023</year>; <volume>13</volume>: <fpage>1743</fpage>.<pub-id pub-id-type="pmid">37629600</pub-id>
</mixed-citation></ref></ref-list></back></article>